ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
COVID vaccines

Indonesia holds off on AstraZeneca vaccine, awaits WHO review

Thailand to go ahead with administering shots on Tuesday after delay last week

AstraZeneca's coronavirus vaccine arrived in Indonesia on March 8, but the country will delay administering it due to reports of blood clots among some recipients in Europe.   © Reuters

JAKARTA (Reuters) -- Indonesia will delay the administering of AstraZeneca's COVID-19 vaccine due to reports of blood clots among some recipients in Europe and would await a review from the World Health Organization (WHO), its health minister said on Monday.

The European Medicines Agency has said there is no indication that the events were caused by the vaccination, a view echoed Friday by the WHO, while AstraZeneca said on Sunday its review has shown no evidence of an increased risk of blood clots.

"To be conservative, the food and drug agency delayed implementation of AstraZeneca (vaccine) as it awaits confirmation from the WHO," health minister Budi Gunadi Sadikin told a parliamentary hearing on Monday.

Indonesia received 1.1 million doses of the AstraZeneca vaccine via the COVAX vaccine-alliance scheme this month and is set to receive some 10 million more in the next two months.

Thailand, which became the first country outside of Europe to delay use of the AstraZeneca shot on Friday, plans to start using the vaccine on Tuesday, officials said, with the prime minister and his cabinet the first to receive it.

The decision will leave Indonesia with just one approved vaccine, developed by China's Sinovac Biotech, for use in its nationwide vaccination drive.

Its immunization program started in January and aims to reach 181.5 million people within a year.

The Southeast Asian country has been grappling with the worst outbreak in the region, having recorded more than 1.4 million infections and 38,500 deaths.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends October 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more